ALX Oncology Holdings Inc. (ALXO) News
Follow ALX Oncology Holdings Inc. (ALXO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
ALXO: Lead assets advance toward phase III, with strong biomarker focus and robust financial runway
Two lead programs are advancing toward pivotal studies, with evorpacept showing strong biomarker-driven efficacy and ALX2004 progressing through dose escalation in multiple tumor types. Financial runway supports operatio
NEWS | Sep 14, 2026, 07:52 PM UTC
L
ALXO: Lead immuno-oncology and ADC programs advance toward pivotal trials with strong biomarker focus
Two lead programs, evorpacept and ALX2004, are advancing toward pivotal studies, with key data readouts expected in the next 12—24 months. Evorpacept's biomarker-driven approach and ALX2004's novel epitope offer strong d
NEWS | Sep 14, 2026, 07:18 PM UTC
L
ALXO: ALX2004 and evorpacept advance toward registrational trials, targeting key oncology indications
ALX2004 is advancing through dose escalation with promising safety and activity signals, aiming for expansion and registrational studies next year. Evorpacept shows strong efficacy in CD47-high breast cancer patients, wi
EQUITY | Sep 09, 2026, 09:58 PM UTC
L
ALX2004 and evorpacept on track for phase III readiness by mid-2025
ALX2004 is advancing through dose escalation toward proof-of-concept in key tumor types by mid-2025. Evorpacept, a biomarker-driven CD47-high cancer program, targets phase III readiness next year.
EQUITY | Sep 09, 2026, 08:45 PM UTC
L
ALX Oncology to present at investor conferences in September
ALX Oncology Holdings said its leadership will present at upcoming investor conferences in September, according to a company announcement.
EQUITY | Sep 02, 2026, 12:07 PM UTC
L
ALXO - ALX Oncology to Present at Upcoming Investor Conferences in September
ALXO - ALX Oncology to Present at Upcoming Investor Conferences in September
EQUITY | Sep 02, 2026, 12:00 PM UTC
L
ALXO - ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ALXO - ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
EARNINGS | Aug 06, 2026, 12:00 PM UTC
L
ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman
ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO ), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the appointm
EQUITY | Jun 30, 2026, 12:12 PM UTC